Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Saw palmetto extract (SPE), SPET-085, is shown to be effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia (BPH), according to a new study by Euromed.
Subscribe to our email newsletter
The study was conducted to assess the in-vitro potency of SPET-085, an inhibitor of the 5alpha-reductase isoenzyme type II, in a cell-free test system.
SPE has been used for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH).
Study results revealed that SPET-085 can effectively inhibit the enzyme linked to BPH, at a lower dose as compared to hexane extracts of saw palmetto.
The study also showed that SPET-085 has bioactivity similar to finasteride, the most commonly prescribed prescription medicine for the treatment of BPH.
Michael Barry, professor of medicine at Harvard Medical School, said: “I look forward to seeing if these interesting results in the laboratory translate into better patient outcomes in the National Institutes of Health-funded Camus study, an ongoing 18 month clinical trial comparing this saw palmetto supplement against a placebo for urinary symptoms attributed to benign prostatic enlargement.”
Joe Veilleux, general manager of Euromed USA, said: “The results of this study verify the activity of our new saw palmetto extract, SPET-085, to help maintain healthy prostate function.
“Euromed is committed to ongoing clinical research to provide scientific evidence which is expected to differentiate SPET-085 from other saw palmetto extracts.”